Xeloda News and Research

RSS
Xeloda is a drug used to treat stage III colon cancer in patients who had surgery to remove the cancer. It is also used to treat metastatic breast cancer that has not improved after treatment with certain other anticancer drugs. Xeloda is being studied in the treatment of other types of cancer. It is taken up by cancer cells and breaks down into 5-fluorouracil, a substance that kills tumor cells. Xeloda is a type of antimetabolite. Also called capecitabine.
NICE decides not to recommend lapatinib for women with advanced breast cancer

NICE decides not to recommend lapatinib for women with advanced breast cancer

ZIOPHARM presents positive data from PICASSO Phase II trial for soft tissue sarcoma at 46th ASCO

ZIOPHARM presents positive data from PICASSO Phase II trial for soft tissue sarcoma at 46th ASCO

ZIOPHARM Oncology to present phase II data from PICASSO trial for soft tissue sarcoma at ASCO meeting

ZIOPHARM Oncology to present phase II data from PICASSO trial for soft tissue sarcoma at ASCO meeting

Aeterna Zentaris posts net loss of $5.9 million for first-quarter 2010

Aeterna Zentaris posts net loss of $5.9 million for first-quarter 2010

Array BioPharma reports 18.4M revenue for third-quarter fiscal 2010

Array BioPharma reports 18.4M revenue for third-quarter fiscal 2010

ZIOPHARM reports a net loss of $17.7 million in first quarter 2010

ZIOPHARM reports a net loss of $17.7 million in first quarter 2010

Genentech submits sBLA for Herceptin plus chemotherapy for advanced HER2-positive stomach cancer

Genentech submits sBLA for Herceptin plus chemotherapy for advanced HER2-positive stomach cancer

Æterna Zentaris Zentaris requests EMA Scientific Advice for Phase 3 program with perifosine

Æterna Zentaris Zentaris requests EMA Scientific Advice for Phase 3 program with perifosine

Keryx Biopharmaceuticals commences Phase 3 registration clinical trial for perifosine

Keryx Biopharmaceuticals commences Phase 3 registration clinical trial for perifosine

Æterna Zentaris commences perifosine Phase 3 registration trial

Æterna Zentaris commences perifosine Phase 3 registration trial

ZIOPHARM Oncology commences Phase I/II study of Zybulin for metastatic breast cancer

ZIOPHARM Oncology commences Phase I/II study of Zybulin for metastatic breast cancer

FDA grants "Fast Track" designation for Genta’s advanced gastric cancer drug tesetaxel

FDA grants "Fast Track" designation for Genta’s advanced gastric cancer drug tesetaxel

Investment report on Keryx Biopharmaceuticals from BeaconEquity.com

Investment report on Keryx Biopharmaceuticals from BeaconEquity.com

Keryx Biopharmaceuticals' perifosine receives FDA Fast Track Designation

Keryx Biopharmaceuticals' perifosine receives FDA Fast Track Designation

FDA grants Keryx Biopharmaceuticals Fast Track designation for perifosine

FDA grants Keryx Biopharmaceuticals Fast Track designation for perifosine

Genta commences Phase 2b trial of tesetaxel in patients with advanced gastric cancer

Genta commences Phase 2b trial of tesetaxel in patients with advanced gastric cancer

ZIOPHARM Oncology reports  fourth quarter net income of $1.0M against loss last year

ZIOPHARM Oncology reports fourth quarter net income of $1.0M against loss last year

Genentech's Avastin combination Phase III study in advanced stomach cancer does not meet primary endpoint

Genentech's Avastin combination Phase III study in advanced stomach cancer does not meet primary endpoint

Keryx Biopharmaceuticals reaches agreement with FDA on SPA for Phase 3 trial of KRX-0401

Keryx Biopharmaceuticals reaches agreement with FDA on SPA for Phase 3 trial of KRX-0401

FDA approves new drug combination for hormone positive and HER2-positive advanced breast cancer

FDA approves new drug combination for hormone positive and HER2-positive advanced breast cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.